February is off to a flying start for our team – Monday has seen our team joining a fantastic Clubhouse room with Elon Musk sharing insights on entrepreneurship, the future of medicine, tech, development of AI within a human brain, and more.

TOPICS COVERED:

▌Mars. “Civilizations fall, and most likely, ours will too. I think for the first time in 4.5 billion years in the history of the earth it is now possible to make life multi-planetary.”

▌Future of AI.
“If AI is super powerful, how do we go along for the ride? Computers communicate at trillions of bits per second…”

Additionally, our Ecosystem has grown with an addition of our latest Ecosystem Partner, Go Global World Community. Go Global World (GGW) is a free global ecosystem where English-speaking founders connect with other entrepreneurs to enter foreign markets and raise business capital.

Partners of Go Global World are Embry–Riddle Aeronautical University (#11 in University ratings of South States of the USA), Technopark SKOLKOVO, Moscow School of Management SKOLKOVO, IBConsulter, RusBase, venture fund UnVentures, Axis Innovation in Israel, Colaborativo – a business community in Mexico, MindHive – a business community in Australia, IT Park, Youth Union in Uzbekistan, Astana Hub in Kazakhstan, Startup News in India, Accelerator Expert Dojo in Los Angeles, USA, and others.

Lastly, we’ve been following the investment patterns and paying close attention to emerging trends. Here, we’re looking at the global medical devices market that is expected to reach USD 612.7 Billion by 2025, growing at a CAGR of 5.4%.

Meridian Cardiovascular Systems are seeking to raise USD 4.5M to develop a novel therapeutic device for the treatment of cardiovascular disease.MCS has a foothold in the market with six patents issued in the US and one additional one pending, and is seeking funds to complete its prototype development.

MCS’ exclusive technology has significant advantages over what is currently available:
against stents (no damage to arterial walls, novel ultrasound, ability to treat asymmetric plaque)
and against surgery (reduced trauma and pain, reduced mortality risk, improved future outlook if occlusion re-occurs, reduced potential for complications such as inadequate wound repair or site infection).
With a highly experienced team and established partnerships, the opportunity is a strong bet to consider. If you’d like to see MCS’ offer materials or request an introduction,
► Register interest in MCS here.

© 2020 KapVista